Johnson D Brooke, Saboorian M Hossein, Duchene David A, Ogan Kenneth, Cadeddu Jeffrey A
Clinical Center for Minimally Invasive Urologic Cancer Treatment, Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9110, USA.
Urology. 2003 Aug;62(2):351-2. doi: 10.1016/s0090-4295(03)00361-3.
Little information is available concerning the morbidity of radiofrequency ablation (RFA) or the evolution of an RFA lesion over time. We report our findings in a kidney removed 1 year after RFA of a 2.3-cm renal tumor. After RFA, the patient experienced flank pain, followed by hydronephrosis, ureteropelvic junction obstruction, and eventual loss of function in the treated kidney. Nephrectomy revealed no residual renal cell carcinoma. RFA can completely destroy renal cell carcinoma in situ without histologic evidence of persistence or recurrence for up to 1 year after treatment. Care must be taken to avoid concurrent damage to the collecting system.
关于射频消融(RFA)的发病率或RFA病灶随时间的演变情况,目前可获取的信息较少。我们报告了对一例2.3厘米肾肿瘤进行RFA治疗1年后切除的肾脏的研究结果。RFA治疗后,患者出现胁腹疼痛,随后出现肾盂积水、输尿管肾盂连接处梗阻,最终治疗侧肾脏功能丧失。肾切除术显示无残留肾细胞癌。RFA可在原位完全摧毁肾细胞癌,治疗后长达1年无持续或复发的组织学证据。必须注意避免同时损伤集合系统。